lntracoronary stenting has been introduced as an adjunct to balloon angioplasty aimed at overcoming its limitations, namely acute vessel closure and late restenosis.
This study reports the first experience with the WiktoP stent implanted in the first 50 consecutive patients. All patients had restenosis of a native coronary artery lesion after prior balloon angioplasty.
The target coronary artery was the left anterior descending artery in 26 patients, the circumflex artery in 7 patients and the right coronary artery in 17 patients. The implantation success rate was 98% (49 of 50 patients). There were no procedural deaths. Acute or subacute thrombotic stent occlusion occurred in 5 patients (10%). All 5 patients sustained a nonfatal acute myocardial infarction. Four of these patients underwent recanalization by means of balloon angioplasty; the remaining patient was referred for bypass surgery. A major bleeding complication occurred in 11 patients (22%): groin bleeding necessitating blood transfusion in 6, gastrointestinal bleeding in 3 and hematuria in 2. Repeat angiography was performed at a mean of 5.6 f 1.1 months in all but 1 patient undergoing implantation. Restenosis, defined by a reduction of 20.72 mm in the minimal luminal diameter or a change in diameter stenosis from < to >_SO%, occurred in 20 (45%) and 13 (29%) patients, respectively. In this first experience, the easiness and high technical success rate of Wiktor stent implantation are overshadowed by a high incidence of subacute stent occlusion and bleeding complications.
Although direct comparison with balloon angioplasty regarding the incidence of subsequent restenosis rate is not possible, the experience reported in this study compares favorably with data reported in other published reports.
(Am J Cardiol 1992;69:598-602) P ercutaneous transluminal coronary balloon angioplasty (PTCA) has established its role as a nonsurgical revascularization procedure in selected patients with obstructive coronary artery disease. Gained operator experience and improved catheter technology has resulted in a high immediate success rate and a low incidence of complications.' These favorable initial results are compromised by the unpredictable problem of late restenosis, occurring in 20 to 40% of the patients after successful PTCA.2-5 Furthermore, there is some evidence that the recurrence of subsequent restenosis after repeat PTCA increases with the number of repeat interventions. 6-9 Intracoronary stents are one of the new technologies that (along with pharmacologic interventions, atherectomy and laser techniques) have entered clinical testing to address this problem.lO Re cently, the first experience with the self-expandable Wallstent@ and the balloon expandable Palmaz-Schatz@ stent have been reported."J2 The stent used in this study is the Medtronic WiktorTM stent which, in contrast to the Wallstent and the Palmaz-Schatz stent, is not a mesh-made stainless steel device but a coil-like prosthe sis made of a single loose interdigitating tantalum wire formed into a sinusoidal wave and configured as a helix. This loose configuration may offer less scaffolding properties compared with the other 2 stents. Therefore, the purpose of this study was to assess the immediate and long-term clinical and angiographic results following Wiktor stent implantation in the first 50 consecutive patients with restenosis following balloon angioplasty of a native coronary artery lesion.
METHODS
Patients: The study group consisted of the first 50 consecutive patients in whom a single Wiktor stent implantation was attempted (Table I ). All patients had recurrence of angina with objective evidence of ischemia due to restenosis of a native coronary artery lesion following PTCA. A first restenosis was documented in 33 patients, a second restenosis in 13 patients and a third in 4 patients. The dilated and stented coronary artery was the left anterior descending artery in 26 patients (52%), the circumflex artery in 7 patients (14%) and the right coronary artery in 17 patients (34%). A written informed consent was required for every patient. The study protocol was approved by the ethics committee of the individual hospitals. The stents used in this study are shown in Figures 1 and 2 . They are described in detail elsewhere as well as the drug protocol associated with stent implantation. 11,13 The angiograms were analyzed using automated edge-detection as previously described.14J5
End points: Primary clinical end points were death, myocardial infarction, bypass surgery or repeat intervention and bleeding complications. All deaths were considered cardiac, unless an unequivocal noncardiac cause could be established. The primary angiographic end point was the change in minimal luminal diameter at the dilated and stented segment at 6 months relative to the baseline. If a revascularization procedure involving the stented segment had been performed before 6 months repeat angiography, the last angiogram before this intervention was used to obtain follow-up values, irrespective of the timing of repeat PTCA (hours, days or weeks). The secondary angiographic end point was the incidence of restenosis defined according to the following criteria: First, a continuous approach was used in which restenosis was defined by a reduction of 10.72 mm in the minimal luminal diameter at follow-up. This change in minimal luminal diameter has been found to be a reliable indicator of angiographic progression of vessel narrowing. This value takes into account the limitations of coronary angiographic measurements and represents twice the long-term variability of repeat measurements of a coronary artery obstruction with the Cardiovascular Angiographic Analysis System. l5 Second, a categorical approach was used in which an increase in diameter stenosis of <50% immediately after stent implantation to 250% at follow-up was used as a cutoff point to define restenosis. This criterion was selected since common clinical practice has continued to express lesion severity as a percentage of stenosis. Values obtained by quantitative angiographic analysis are expressed as mean f SD. The means for each angiographic variable before PTCA, after PTCA, immediately after stent implantation and at follow-up were compared by analysis of variance. If significant differences were found, 2-tailed t tests were applied to paired data. A statistical probability of <0.05 was considered significant. In the patient with the miss- ter implantation. ing follow-up angiogram and no clinical evidence of restenosis, imputation of the minimal luminal diameter at follow-up was performed: the minimal luminal diameter at follow-up of this patient was calculated by subtracting the mean change of the minimal luminal diameter of the entire study population from the value of the minimal luminal diameter immediately after stent implantation of this particular patient.
RESULTS

Clinical results:
The implantation success rate was 98% (49 of 50 attempted implants). In 1 patient, the stent could not be delivered at the target site due to the inability to cross a tortuous proximal right coronary artery. There were no procedural related deaths. However, subacute thrombotic stent occlusion occurred in 5 patients (10%) while still in the hospital. patient, day 4 = 1 patient, and day 5 = 2 patients. Four patients underwent recanalization by means of conventional balloon angioplasty. In 1 of these patients adjunctive thrombolytic therapy was used. In the remaining patient, repeat PTCA was not attempted because retrospective analysis of the implantation angiogram revealed incomplete stent expansion. This patient was referred for emergency bypass surgery. All 5 patients sustained a nonfatal acute myocardial infarction (mean f SD, creatine phosphokinase 1,797 f 1,849 U/liter). A major bleeding complication occurred in 11 patients (22%): 6 patients sustained a groin hematoma necessitating blood transfusion, 3 patients had a gastrointestinal bleeding (2 duodenal ulcers, 1 intestinal polyps) and 2 patients had hematuria. One patient had an infected pharyngeal hematoma caused by acenocoumarol therapy at 3 months after implant. During follow-up, 1 patient died 3 months after stent implantation following prostate surgery. This patient had a history of bypass surgery, mitral valve replacement and multiple PTCA's. Because of severe disabling heart failure, he was screened for heart transplantation. During this period, a prostate adenoma was found and surgically removed. The second day after surgery, he died because of heart failure. Although necropsy was not performed, death was not considered stent-related because there was no clinical evidence of restenosis. No patient sustained an acute myocardial infarction. Three patients (6%) underwent bypass surgery (2 patients 3.5 months and 1 patient 6 months after the stent implantation). There was a significant improvement in functional class at 6-month follow-up. Before stent implantation, 10 patients were in class I, 6 in class II, 14 in class III and 20 in class IV, according to the Canadian Cardiovascular Society. At follow-up, 34 patients were in class I, 9 in class II, 4 in class III and 3 in class IV.
Angiographic results: Wiktor stent implantation resulted in a further significant increase in minimal luminal diameter, from 1.80 f 0.32 mm immediately following balloon angioplasty to 2.45 f 0.35 mm immediately after stent implantation. This was associated with a reduction in diameter stenosis from 34 f 11 to 18 f 7% (Table II) . There was no change in the reference diameter before and after PTCA (2.81 f 0.48 and 2.80 f 0.48 mm, respectively, p = not significant). However, there was a significant increase after stent implantation (2.98 f 0.42 mm, p <O.OOOOl), which was confirmed at follow-up (2.91 f 0.55 mm). In most patients the measured diameter of the balloon when fully inflated was higher than the measured diameter of the stent ( Figure  2 ). During maximal inflation the mean diameter of the balloon for the total study group was 2.98 f 0.44 mm. The mean diameter of the stented segment immediately after implantation was 2.88 f 0.43 mm. This implies a recoil of 0.10 f 0.36 mm (p <0.03).
Repeat angiography was performed in all patients with successful stent implantation (49 patients), except in 1, who died 3 months after stent implantation follow- ing prostate surgery. There was no clinical evidence of restenosis in this patient. The mean time interval between stent implantation and control study was 5.6 f 1.1 months. Overall, the minimal luminal diameter was found to have decreased from 2.45 f 0.35 to 1.59 f 0.79 mm (p <O.OOOOl). The percentage of stenosis had increased from 18 f 7 to 45 f 25% (p <O.OOOl, Table  II ). When only patients without clinical evidence of subacute vessel closure during hospital stay (44 patients) were included, the minimal luminal diameter and percentage of stenosis were 1.78 f 0.60 mm and 39 f 18%, respectively (Table II) . Figure 3 displays the cumulative distribution of the minimal luminal diameter and its changes (immediately after balloon angioplasty and stent implantation and at follow-up). The additional increase in minimal luminal diameter immediately after stent implantation is lost at follow-up.
The incidence of restenosis depended on the delinition used. When a change of 10.72 mm in minimal luminal diameter was used as the criterion, restenosis was observed within the stent in 19 patients (43%) and in the segment immediately distal to the stent in 1 (2%) of the 44 patients without clinical evidence of subacute stent occlusion during hospital stay. Of these 44 patients, the percentage of stenosis at follow-up had increased to 250% within the stent in 12 (27%) and in the segment distal to the stent in 1 (2%). Therefore, the total restenosis rate was 45% according to the 0.72 mm criterion and 29% according to the 50% diameter stenosis criterion (Figure 4 ).
DISCUSSION
Clinical results: Intracoronary stents are currently being tested in clinical practice to reduce the incidence of acute vessel occlusion and restenosis following balloon angioplasty. Several stems are available, each with its own specific design, composition and physicochemical behavior once implanted. Implanting foreign body material implies an increased risk for acute thrombosis. Therefore, a stringent anticoagulation protocol is mandatory. Despite the protocol previously described, a thrombotic subacute stent occlusion occurred in 5 patients (10%). Three of these patients did not receive dextran and 1 patient was not properly treated with acenocoumarol. Of the 44 patients without clinical evidence of subacute stent occlusion during hospital stay, only 6 (14%) did not receive dextran. Unfortunately, since central assessment of anticoagulation was not performed, the exact role of the failure of anticoagulation with respect to subacute thrombotic stent occlusion cannot be elucidated. Although it is tempting to speculate that suboptimal anticoagulation may be the main cause of stent occlusion, other pathophysiologic mechanisms also may be involved. Before stent implantation, balloon angioplasty is performed to facilitate stent delivery. The disruptive action of the balloon may cause intimal dissection, which in turn may be the primary cause of an ensuing thrombotic event. Furthermore, patients' related factors such as acute ischemic syndromes, procedurerelated factors such as technical difficult stent implantation and angiographic related factors such as small vessel size and total occlusion may predispose to thrombotic stent occlusion. In this study group, no difference in vessel size was seen in patients with and without subacute stent occlusion (reference diameter 2.8 f 0.4 and 2.8 f 0.5 mm, respectively (p = not significant). The reported subacute stent occlusion rate compares very favorably with the initial Wallstent experience (20% in 105 patients), but is similar to the subacute occlusion rate following the extended Wallstent experience (12% in an additional 160 patients). l 1,16 However, it contrasts sharply with the incidence of 0.6% following PalmazSchatz stent implantation. l2 True comparison is not possible because the studies differ in methods for patient selection, indication for stent implantation and type of vessel stented. Furthermore, the very low incidence of 0.6% reported by Schatz, has not been confirmed by a recent study, using the same device.17 In this latter study, an incidence of 16% is reported. Probably, the incidence of subacute stent occlusion may be reduced by a more detailed coagulation monitoring. Indeed, recent work indicates that measurement of prothrombin fragment 1 + 2 and its changes after stent implantation may be predictive for subacute thrombotic stent occlusion.'8
Another matter of concern is the risk of bleeding, inherently associated with aggressive anticoagulation. The incidence of bleeding is negligible after PTCA but is substantial when a combination of intravenous and oral anticoagulant drugs are administered.12 The most serious bleeding complication is intracranial hemorrhage, which occurred in 1 of 174 patients following Palmaz-Schatz stent implantation and in 3 of 265 patients following Wallstent implantation.12J6 Another aspect to be considered regarding anticoagulation is the longer period of hospitalization, which in turn increases the overall costs of the procedure. 19 In this study, the hospital stay was (mean f SD) 11.8 f 7.4 days for the entire study population.
Angiographic results: The smaller mean diameter of the stented segment (2.88 f 0.43 mm) compared with the measured diameter of the fully expanded balloon (2.98 f 0.44 mm) suggests some recoil of the stented segment. This minimal recoil appears to 'be a true phenomenon since the accuracy and the precision of the quantitative coronary angiography system used in this study is -30 and 90 CL, respectively.15 Furthermore, recoil has also been observed, although to a larger extent, after Wiktor stent implantation in Yorkshire pigs.2o The more pronounced recoil (10%) observed in the animal model compared with recoil observed in this study (3%) may be explained by the fact that in the former animal study the stent was implanted in normal coronary arteries. All these angiographic data indicate that in contrast to balloon angioplasty, where recoil amounting to 50% has been documented, the Wiktor stent appropriately scaffolds the vessel. 21 Restenosis and recurrence of restenosis remains the major limitation of (repeat) PTCA. Whether intracoronary stents can address this issue appropriately is still unknown. There are some encouraging data from preliminary reports.22.23 However, firm conclusions cannot be drawn, since these data stem from nonrandomized studies in which single and multiple stent implantations have been performed in both native coronary arteries and venous bypass grafts have been performed in patients with either acute ischemic syndromes or stable angina for a variety of indications (primary stent implantation, restenosis, bail out). Patients undergoing repeat PTCA appear to be at a higher risk for recurrence of restenosis after repeat intervention. The angiographic documented restenosis rate increases from 34% after a second dilatation to 40% after a fourth dilatation.6,g This is probably an underestimation of the actual incidence owing to incomplete angiographic follow-up. Repeat angiography is mandatory in all patients, even in patients free of angina at follow-up since approximately 25% of the patients with restenosis are asymptomatic. Taking into account the limitations of ,these nonrandomized observational studies, as is done in this study, the incidence of 29% restenosis using the 50% diameter stenosis criterion compares favorably with data from those former studies. Indeed, randomized studies are needed to define the exact role of intracoronary stenting in the prevention of (recurrent) restenosis.
